Models in research of pharmacoresistant epilepsy: Present and future in development of antiepileptic drugs

Current Medicinal Chemistry

Volumn 21, Issue 6, 2014, Pages 689-703

  Kovacs R ^a   Heinemann, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood brain barrier; Brain slices; Electrical kindling; Kainate; Multidrug transporter; Neuroinflammation; Pharmacoresistance; Pilocarpine; Slice cultures; Temporal lobe epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BUMETANIDE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FUROSEMIDE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LOSIGAMONE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; POTASSIUM BROMIDE; PREGABALIN; RAPAMYCIN; RETIGABINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ARTICLE; AUDIOGENIC SEIZURE; BLOOD BRAIN BARRIER; BRAIN SLICE; COMPLEX PARTIAL SEIZURE; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG RESISTANCE; DRUG RETENTION; EPILEPSY; EPILEPTOGENESIS; FEBRILE CONVULSION; GENERALIZED EPILEPSY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JUVENILE ANIMAL; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; SEIZURE; TONIC CLONIC SEIZURE; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS;

EID: 84893316677     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867320666131119152613     Document Type: Article

References (195)

1. Picot, M.C.; Baldy-Moulinier, M.; Daurès, J.P.; Dujols, P.; Crespel, A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia, 2008, 49(7), 1230-1238.
2. Schmidt, D.; Löscher, W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia, 2005, 46(6), 858-877.
3. Kwan, P.; Arzimanoglou, A.; Berg, A.T.; Brodie, M.J.; Allen, H.W.; Mathern, G.; Moshé, S.L.; Perucca, E.; Wiebe, S.; French, J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6), 1069-1077.
4. Remy, S.; Beck, H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain, 2006, 129(Pt 1), 18-35.
5. Gorter, J.A.; Potschka, H. Drug Resistance. In: Jasper's Basic Mechanisms of the Epilepsies. Noebels J.L.; Avoli, M.; Rogawski, M.A.; Olsen, R.W.; Delgado-Escueta, A.V., Eds.; Bethesda (MD): National Center for Biotechnology Information (US), 2012; 4th edition.
6. Berg, A.T.; Levy, S.R.; Novotny, E.J.; Shinnar, S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia, 1996, 37(1), 24-30.
7. Regesta, G.; Tanganelli, P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res., 1999, 34(2-3), 109-122.
8. Kanazawa, O. Refractory grand mal seizures with onset during infancy including severe myoclonic epilepsy in infancy. Brain Dev., 2001, 23(7), 749-756.
9. Schmidt, D.; Löscher, W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr., 2009, 9(2), 47-52.
10. Heinemann, U.; Kann, O.; Remy, S.; Beck, H. Novel mechanisms underlying drug resistance in temporal lobe epilepsy. Adv. Neurol., 2006, 97, 85-95.
11. Lehmann, T.N.; Gabriel, S.; Kovacs, R.; Eilers, A.; Kivi, A.; Schulze, K.; Lanksch, W.R.; Meencke, H.J.; Heinemann, U. Alterations of neuronal connectivity in area CA1 of hippocampal slices from temporal lobe epilepsy patients and from pilocarpine-treated epileptic rats. Epilepsia, 2000, 41 Suppl 6, S190-194.
12. Löscher, W.; Schmidt, D. New Horizons in the development of antiepileptic drugs: Innovative strategies. Epilepsy Res., 2006, 69(3), 183-272.
13. Ghosh, C.; Puvenna, V.; Gonzalez-Martinez, J.; Janigro, D.; Marchi, N. Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. Curr. Drug. Metab., 2011, 12(8), 742-749.
14. Rogawski, M.A.; Johnson, M.R. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr., 2008, 8(5), 127-130.
15. Cheah, C.S.; Yu, F.H.; Westenbroek, R.E.; Kalume. F.K.; Oakley, J.C.; Potter, G.B.; Rubenstein, J.L.; Catterall, W.A. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(36), 14646-14651.
16. Vreugdenhil, M.; Wadman, W.J. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia, 1999, 40(11), 1512-1522.
17. Remy, S.; Gabriel, S.; Urban, B.W.; Dietrich, D.; Lehmann, T.N.; Elger, C.E.; Heinemann, U.; Beck, H. A. Novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol., 2003, 53(4), 469-479.
18. Gibbs, J.W.; Shumate, M.D.; Coulter, D.A. Differential epilepsyassociated alterations in postsynaptic GABA(A) receptor function in dentate granule and CA1 neurons. J. Neurophysiol., 1997, 77(4), 1924-1938.
19. Volk, H.A.; Arabadzisz, D.; Fritschy, J.M.; Brandt, C.; Bethmann, K.; Löscher, W. Antiepileptic drug-resistant rats differ from drugresponsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol. Dis., 2006, 21(3), 633-646.
20. Ferando, I.; Mody, I. GABAA receptor modulation by neurosteroids in models of temporal lobe epilepsies. Epilepsia, 2012, 53 Suppl 9, 89-101.
21. Coulter, D.A. Chronic epileptogenic cellular alterations in the limbic system after status epilepticus. Epilepsia, 1999, 40 Suppl 1, S23-33.
22. Van Vliet, E.A.; Aronica, E.; Redeker, S.; Boer, K.; Gorter, J.A. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia, 2009, 50(3), 422-433.
23. Rogawski, M.A.; Taylor, C.P. Calcium Channel α2-δ Subunit, A New Antiepileptic Drug Target, Epilepsy Res., 2006, 69(3), 183-272.
24. Noam, Y.; Bernard, C.; Baram, T.Z. Towards an integrated view of HCN channel role in epilepsy. Curr. Opin. Neurobiol., 2011, 21(6), 873-879.
25. Tishler, D.M.; Weinberg, K.I.; Hinton, D.R.; Barbaro, N.; Annett, G.M.; Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia, 1995, 36(1), 1-6.
26. Lazarowski, A.; Sevlever, G.; Taratuto, A.; Massaro, M.; Rabinowicz, A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr. Neurol., 1999, 21(4), 731-734.
27. Sisodiya, S.M.; Lin, W.R.; Harding, B.N.; Squier, M.V.; Thom, M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain, 2002, 125(Pt 1), 22-31.
28. Dallas, S.; Miller, D.S.; Bendayan, R. Multidrug resistanceassociated proteins: expression and function in the central nervous system. Pharmacol. Rev., 2006, 58(2), 140-161.
29. Aronica, E.; Sisodiya, S.M.; Gorter, J.A. Cerebral expression of drug transporters in epilepsy. Adv. Drug Deliv. Rev., 2012, 64(10), 919-929.
30. Dombrowski, S.M.; Desai, S.Y.; Marroni, M.; Cucullo, L.; Goodrich, K.; Bingaman, W.; Mayberg, M.R.; Bengez, L.; Janigro, D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia, 2001, 42(12), 1501-1506.
31. Abbott, N.J.; Khan, E.U.; Rollinson, C.M.; Reichel, A.; Janigro, D.; Dombrowski, S.M.; Dobbie, M.S.; Begley, D.J. Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found Symp., 2002, 243, 38-47.
32. Sisodiya, S.M.; Martinian, L.; Scheffer, G.L.; van der Valk, P.; Scheper, R.J.; Harding, B.N.; Thom, M. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol. Appl. Neurobiol., 2006, 32(1), 51-63.
33. Aronica, E.; Gorter, J.A.; Ramkema, M.; Redeker, S.; Ozbas- Gerçeker, F.; van Vliet, E.A.; Scheffer, G.L.; Scheper, R.J.; van der Valk, P.; Baayen, J.C.; Troost, D. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia, 2004, 45(5), 441-451.
34. Kovács, R.; Raue, C.; Gabriel, S.; Heinemann, U. Functional test of multidrug transporter activity in hippocampal-neocortical brain slices from epileptic patients. J. Neurosci. Methods., 2011, 200(2), 164-172.
35. Baltes, S.; Gastens, A.M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 2007, 52(2), 333-346.
36. Rivers, F.; O'Brien, T.J.; Callaghan, R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur. J. Pharmacol., 2008, 598(1-3), 1-8.
37. Löscher, W.; Luna-Tortós, C.; Römermann, K.; Fedrowitz, M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr. Pharm. Des., 2011, 17(26), 2808-2828.
38. Potschka, H.; Fedrowitz, M.; Löscher, W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. Epilepsia, 2003, 44(12), 1479-1486.
39. Tate, S.K.; Sisodiya, S.M. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin. Pharmacother., 2007, 8(10), 1441-1449.
40. Bournissen, F.G.; Moretti, M.E.; Juurlink, D.N.; Koren, G.; Walker, M.; Finkelstein, Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia, 2009, 50(4), 898-903.
41. Jandová, K.; Päsler, D.; Antonio, L.L.; Raue, C.; Ji, S.; Njunting, M.; Kann, O.; Kovács, R.; Meencke, H.J.; Cavalheiro, E.A.; Heinemann, U.; Gabriel, S.; Lehmann, T.N. Carbamazepineresistance in the epileptic dentate gyrus of human hippocampal slices. Brain, 2006, 129(Pt 12), 3290-3306.
42. Brandt, C.; Bethmann, K.; Gastens, A.M.; Löscher, W. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis., 2006, 24(1), 202-211.
43. Van Vliet, E.A.; van Schaik, R.; Edelbroek, P.M.; Redeker, S.; Aronica, E.; Wadman, W.J.; Marchi, N.; Vezzani, A.; Gorter, J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia, 2006, 47(4), 672-680.
44. Cossart, R.; Dinocourt, C.; Hirsch, J.C.; Merchan-Perez, A.; De Felipe, J.; Ben-Ari, Y.; Esclapez, M.; Bernard, C. Dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy. Nat. Neurosci., 2001, 4(1), 52-62.
45. Prince, D.A.; Parada, I.; Graber, K. Traumatic Brain Injury and Posttraumatic Epilepsy In: Jasper's Basic Mechanisms of the Epilepsies Noebels, J.L.; Avoli, M.; Rogawski, M.A.; Olsen, R.W.; Delgado-Escueta, A.V., Eds.; Bethesda (MD): National Center for Biotechnology Information (US), 2012; 4th edition.
46. Cohen, I.; Navarro, V.; Le Duigou, C.; Miles, R. Mesial temporal lobe epilepsy: a pathological replay of developmental mechanisms? Biol. Cell., 2003, 95(6), 329-333.
47. Dzhala, V.I.; Talos, D.M.; Sdrulla, D.A.; Brumback, A.C.; Mathews, G.C.; Benke, T.A.; Delpire, E.; Jensen, F.E.; Staley, K.J. NKCC1 transporter facilitates seizures in the developing brain. Nat. Med., 2005, 11(11), 1205-1213.
48. Ben-Ari, Y. Seizures beget seizures: the quest for GABA as a key player. Crit. Rev. Neurobiol., 2006, 18(1-2), 135-144.
49. Bragin, D.E.; Sanderson, J.L.; Peterson, S.; Connor, J.A.; Müller, W.S. Development of epileptiform excitability in the deep entorhinal cortex after status epilepticus. Eur. J. Neurosci., 2009, 30(4), 611-624.
50. Ben-Ari, Y.; Khalilov, I.; Kahle, K.T.; Cherubini, E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist, 2012, 18(5), 467-486.
51. Wahab, A.; Albus, K.; Heinemann, U. Age- and region-specific effects of anticonvulsants and bumetanide on 4-aminopyridineinduced seizure-like events in immature rat hippocampal-entorhinal cortex slices. Epilepsia, 2011, 52(1), 94-103.
52. Kahle, K.T.; Barnett, S.M.; Sassower, K.C.; Staley, K.J. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J. Child Neurol., 2009, 24(5), 572-576.
53. Nardou, R.; Yamamoto, S.; Chazal, G.; Bhar, A.; Ferrand, N.; Dulac, O.; Ben-Ari, Y.; Khalilov, I. Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital. Brain, 2011, 134(Pt 4), 987-1002.
54. Huberfeld, G.; Wittner, L.; Clemenceau, S.; Baulac, M.; Kaila, K.; Miles, R.; Rivera, C. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J. Neurosci., 2007, 27(37), 9866-9873.
55. Kann, O.; Kovács, R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol., 2007, 292(2), C641-657.
56. Pfeiffer, M.; Draguhn, A.; Meierkord, H.; Heinemann, U. Effects of gamma-aminobutyric acid (GABA) agonists and GABA uptake inhibitors on pharmacosensitive and pharmacoresistant epileptiform activity in vitro. Br. J. Pharmacol., 1996, 119(3), 569-577.
57. Kovács, R.; Schuchmann, S.; Gabriel, S.; Kann, O.; Kardos, J.; Heinemann, U. Free radical-mediated cell damage after experimental status epilepticus in hippocampal slice cultures. J. Neurophysiol., 2002, 88(6), 2909-2918.
58. Vielhaber, S.; Von Oertzen, J.H.; Kudin, A.F.; Schoenfeld, A.; Menzel, C.; Biersack, H.J.; Kral, T.; Elger, C.E.; Kunz, W.S. Correlation of hippocampal glucose oxidation capacity and interictal FDG-PET in temporal lobe epilepsy. Epilepsia, 2003, 44(2), 193-199.
59. Kann, O.; Kovács, R.; Njunting, M.; Behrens, C.J.; Otáhal, J.; Lehmann, T.N.; Gabriel, S.; Heinemann, U. Metabolic dysfunction during neuronal activation in the ex vivo hippocampus from chronic epileptic rats and humans. Brain, 2005, 128(Pt 10), 2396-2407.
60. Kudin, A.P.; Zsurka, G.; Elger, C.E.; Kunz, W.S. Mitochondrial involvement in temporal lobe epilepsy. Exp. Neurol., 2009, 218(2), 326-332.
61. Folbergrová, J.; Kunz, W.S. Mitochondrial dysfunction in epilepsy. Mitochondrion, 2012, 12(1), 35-40.
62. McDaniel, S.S.; Rensing, N.R.; Thio, L.L.; Yamada, K.A.; Wong, M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia, 2011, 52(3), e7-11.
63. Milder, J.; Patel, M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res., 2012, 100(3), 295-303.
64. Wallace, D.C.; Fan, W.; Procaccio, V. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol., 2010, 5, 297-348.
65. Erecinska, M.; Nelson, D.; Daikhin, Y.; Yudkoff, M. Regulation of GABA level in rat brain synaptosomes: fluxes through enzymes of the GABA shunt and effects of glutamate, calcium, and ketone bodies. J. Neurochem., 1996, 67, 2325-2334
66. Omote, H.; Miyaji, T.; Juge, N.; Moriyama, Y. Vesicular neurotransmitter transporter: bioenergetics and regulation of glutamate transport. Biochemistry, 2011, 50(25), 5558-5565.
67. Bough, K.J.; Wetherington, J.; Hassel, B.; Pare, J.F.; Gawryluk, J.W.; Greene, J.G.; Shaw, R.; Smith, Y.; Geiger, J.D.; Dingledine, R.J. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol., 2006, 60(2), 223-235.
68. Jarrett, S.G.; Milder, J.B.; Liang, L.P.; Patel, M. The ketogenic diet increases mitochondrial glutathione levels. J. Neurochem., 2008, 106, 1044-1051.
69. Cacheaux, L.P.; Ivens, S.; David, Y.; Lakhter, A.J.; Bar-Klein, G.; Shapira, M.; Heinemann, U.; Friedman, A.; Kaufer, D. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J. Neurosci., 2009, 29(28), 8927-8935.
70. Steinhäuser, C.; Seifert, G.; Bedner, P. Astrocyte dysfunction in temporal lobe epilepsy: K+ channels and gap junction coupling. Glia, 2012, 60(8), 1192-1202.
71. Gabriel, S.; Kivi, A.; Kovács, R.; Lehmann, T.N.; Lanksch, W.R.; Meencke, H.J.; Heinemann, U. Effects of barium on stimulusinduced changes in [K+]o and field potentials in dentate gyrus and area CA1 of human epileptic hippocampus. Neurosci. Lett., 1998, 249(2-3), 91-94.
72. Kivi, A.; Lehmann, T.N.; Kovács, R.; Eilers, A.; Jauch, R.; Meencke, H.J., von Deimling, A.; Heinemann, U.; Gabriel, S. Effects of barium on stimulus-induced rises of [K+]o in human epileptic non-sclerotic and sclerotic hippocampal area CA1. Eur. J. Neurosci., 2000, 12(6), 2039-2048.
73. Jauch, R.; Windmüller, O.; Lehmann, T.N.; Heinemann, U.; Gabriel, S. Effects of barium, furosemide, ouabaine and 4,4'- diisothiocyanatostilbene-2, 2'-disulfonic acid (DIDS) on ionophoretically- induced changes in extracellular potassium concentration in hippocampal slices from rats and from patients with epilepsy. Brain Res., 2002, 925(1), 18-27.
74. Binder, D.K.; Steinhäuser, C. Functional changes in astroglial cells in epilepsy Glia, 2006, 54(5), 358-368.
75. Kovács, R.; Heinemann, U.; Steinhäuser, C. Mechanisms underlying blood-brain barrier dysfunction in brain pathology and epileptogenesis: role of astroglia. Epilepsia, 2012, 53(Suppl 6), 53-59.
76. Potschka, H. Animal models of drug-resistant epilepsy. Epileptic Disord., 2012, 14(3), 226-234.
77. Leite, J.P., Garcia-Cairasco, N., Cavalheiro, E.A. New insights from the use of pilocarpine and kainate models. Epilepsy Res., 2002, 50(1-2):93-103.
78. Dubé, C.M.; Brewster, A.L.; Baram, T.Z. Febrile seizures: mechanisms and relationship to epilepsy. Brain Dev., 2009, 31(5), 366-371.
79. Löscher, W.; Jäckel, R.; Czuczwar, S.J. Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp. Neurol., 1986, 93(1), 211-226.
80. Williams, P.A.; Hellier, J.L.; White, A.M.; Staley, K.J.; Dudek, F.E. Development of spontaneous seizures after experimental status epilepticus: implications for understanding epileptogenesis. Epilepsia, 2007, 48(Suppl 5), 157-163.
81. Collins, R.L.; Fuller, J.L. Audiogenic seizure prone (asp): a gene affecting behavior in linkage group 8 of the mouse. Science, 1968, 162(3858), 1137-1139.
82. Marescaux, C.; Vergnes, M.; Depaulis, A. Genetic absence epilepsy in rats from Strasbourg - a review. J. Neural Transm. Suppl., 1992, 35, 37-69.
83. Van Luijtelaar, G.; Sitnikova, E. Global and focal aspects of absence epilepsy: the contribution of genetic models. Neurosci. Biobehav. Rev., 2006, 30(7), 983-1003.
84. Gower, A.J.; Hirsch, E.; Boehrer, A.; Noyer, M.; Marescaux, C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res., 1995, 22(3), 207-213.
85. Sarkisova, K.; van Luijtelaar, G. The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2011, 35(4), 854-876.
86. Dailey, J.W.; Yan, Q.S.; Adams-Curtis, L.E.; Ryu, J.R.; Ko, K.H.; Mishra, P.K.; Jobe, P.C. Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci., 1996, 58(4), 259-266.
87. Wilcox, K.S.; Dixon-Salazar, T.; Sills, G.J.; Ben-Menachem, E.; Steve White, H.; Porter, R.J.; Dichter, M.A.; Moshé, S.L.; Noebels, J.L.; Privitera, M.D.; Rogawski, M.A. Issues related to development of new antiseizure treatments. Epilepsia, 2013, 54(Suppl 4), 24-34.
88. Bankstahl, M.; Müller, C.J.; Wilk, E.; Schughart, K.; Löscher, W. Generation and characterization of pilocarpine-sensitive C57BL/6 mice as a model of temporal lobe epilepsy. Behav. Brain Res., 2012, 230(1), 182-191.
89. Goddard, G.V. Development of epileptic seizures through brain stimulation at low intensity. Nature, 1967, 214(5092), 1020-1021.
90. Lothman, E.W.; Bennett, J.P.; Perlin, J.B. Alterations in neurotransmitter amino acids in hippocampal kindled seizures. Epilepsy Res., 1987, 1(6), 313-320.
91. Sutula, T.P.; Dudek, F.E. Unmasking recurrent excitation generated by mossy fiber sprouting in the epileptic dentate gyrus: an emergent property of a complex system. Prog. Brain Res., 2007, 163, 541-563.
92. Löscher, W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res., 2002, 50(1-2), 105-123.
93. Bialer, M.; White, H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9(1), 68-82.
94. Mody, I.; Heinemann, U. NMDA receptors of dentate gyrus granule cells participate in synaptic transmission following kindling. Nature, 1987, 326(6114), 701-704.
95. Heinemann, U., Draguhn, A.; Ficker, E.; Stabel, J.; Zhang, C.L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia, 1994, 35(Suppl 5), S10-21.
96. Buckmaster, P.S.; Dudek, F.E. Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J. Comp. Neurol., 1997, 385(3), 385-404.
97. Ben-Ari, Y. Kainate and Temporal Lobe Epilepsies: 3 decades of progress. In: Jasper's Basic Mechanisms of the Epilepsies. Noebels, J.L.; Avoli, M.; Rogawski, M.A.; Olsen, R.W.; Delgado-Escueta, A.V., Eds.; Bethesda (MD): National Center for Biotechnology Information (US), 2012; 4th edition.
98. Turski, L.; Cavalheiro, E.A.; Czuczwar, S.J.; Turski, W.A.; Kleinrok, Z. The seizures induced by pilocarpine: behavioral, electroencephalographic and neuropathological studies in rodents. Pol. J. Pharmacol. Pharm., 1987, 39(5), 545-555.
99. Rigau, V.; Morin, M.; Rousset, M.C.; de Bock, F.; Lebrun, A.; Coubes, P.; Picot, M.C.; Baldy-Moulinier, M.; Bockaert, J.; Crespel, A.; Lerner-Natoli, M. Angiogenesis is associated with bloodbrain barrier permeability in temporal lobe epilepsy. Brain, 2007, 130(Pt 7), 1942-1956.
100. Ndode-Ekane, X.E.; Hayward, N.; Gröhn, O.; Pitkänen, A. Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. Neuroscience, 2010, 166(1), 312-332.
101. Seiffert, E.; Dreier, J.P.; Ivens, S.; Bechmann, I.; Tomkins, O.; Heinemann, U.; Friedman, A. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J. Neurosci., 2004, 24(36), 7829-7836.
102. Lemos, T.; Cavalheiro, E.A. Suppression of pilocarpine-induced status epilepticus and the late development of epilepsy in rats. Exp. Brain Res., 1995, 102(3), 423-428.
103. Curia, G.; Longo, D.; Biagini, G.; Jones, R.S., Avoli, M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods., 2008, 172(2), 143-57.
104. Chauvière, L.; Doublet, T.; Ghestem, A.; Siyoucef, S.S.; Wendling, F.; Huys, R., Jirsa, V.; Bartolomei, F.; Bernard, C. Changes in interictal spike features precede the onset of temporal lobe epilepsy. Ann. Neurol., 2012, 71(6), 805-814.
105. Sandow, N.; Zahn, R.K.; Gabriel, S.; Heinemann, U.; Lehmann, T.N. Glutamine induces epileptiform discharges in superficial layers of the medial entorhinal cortex from pilocarpine-treated chronic epileptic rats in vitro. Epilepsia, 2009, 50(4), 849-858.
106. Staley, K.; Hellier, J.L.; Dudek, F.E. Do interictal spikes drive epileptogenesis? Neuroscientist, 2005, 11(4), 272-276.
107. Chauvière, L.; Rafrafi, N.; Thinus-Blanc, C.; Bartolomei, F.; Esclapez, M.; Bernard, C. Early deficits in spatial memory and theta rhythm in experimental temporal lobe epilepsy. J. Neurosci., 2009, 29(17), 5402-5410
108. Dudek, F.E.; Staley, K.J. Seizure probability in animal models of acquired epilepsy: a perspective on the concept of the preictal state. Epilepsy Res., 2011, 97(3), 324-331.
109. Engel, J. Jr.; Brown, W.J.; Kuhl, D.E.; Phelps, M.E.; Mazziotta, J.C.; Crandall, P.H. Pathological findings underlying focal tempo ral lobe hypometabolism in partial epilepsy. Ann. Neurol., 1982, 12(6), 518-528.
110. Chassidim, Y.; Veksler, R.; Lublinsky, S.; Pell, G.S.; Friedman, A.; Shelef, I. Quantitative imaging assessment of blood-brain barrier permeability in humans. Fluids Barriers CNS, 2013, 10(1), 9.
111. Holtkamp, M.; Othman, J.; Buchheim, K.; Meierkord, H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J. Neurol. Neurosurg. Psychiatry, 2005, 76(4), 534-539.
112. Anderson, W.W.; Lewis, D.V.; Swartzwelder, H.S.; Wilson, W.A. Magnesium-free medium activates seizure-like events in the rat hippocampal slice. Brain Res., 1986, 398(1), 215-219.
113. Walther, H.; Lambert, J.D.; Jones, R.S.; Heinemann, U.; Hamon, B. Epileptiform activity in combined slices of the hippocampus, subiculum and entorhinal cortex during perfusion with low magnesium medium. Neurosci. Lett., 1986, 69(2), 156-161.
114. Avoli, M.; de Curtis, M. GABAergic synchronization in the limbic system and its role in the generation of epileptiform activity, Prog. Neurobiol., 2011, 95(2), 104-132.
115. Schuchmann, S.; Buchheim, K.; Meierkord, H.; Heinemann, U. A relative energy failure is associated with low-Mg2+ but not with 4- aminopyridine induced seizure-like events in entorhinal cortex. J. Neurophysiol., 1999, 81(1), 399-403.
116. Kovács, R.; Schuchmann, S.; Gabriel, S.; Kardos, J.; Heinemann, U. Ca2+ signalling and changes of mitochondrial function during low-Mg2+-induced epileptiform activity in organotypic hippocampal slice cultures. Eur. J. Neurosci., 2001, 13(7), 1311-1319.
117. Zhang, C.L.; Dreier, J.P.; Heinemann, U. Paroxysmal epileptiform discharges in temporal lobe slices after prolonged exposure to low magnesium are resistant to clinically used anticonvulsants. Epilepsy Res., 1995, 20(2), 105-111.
118. Dreier, J.P.; Zhang, C.L.; Heinemann, U. Phenytoin, phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but can prevent its development. Acta Neurol. Scand., 1998, 98(3), 154-160.
119. Brückner, C.; Heinemann, U. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4- aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res., 2000, 859(1), 15-20.
120. Smith, M.D.; Adams, A.C.; Saunders, G.W.; White, H.S.; Wilcox, K.S. Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro. Epilepsy Res., 2007, 74(2-3), 97-106.
121. Wozny, C.; Gabriel, S.; Jandova, K.; Schulze, K.; Heinemann, U.; Behr, J. Entorhinal cortex entrains epileptiform activity in CA1 in pilocarpine-treated rats. Neurobiol. Dis., 2005, 19(3), 451-460.
122. Zimmerman, G.; Njunting, M.; Ivens, S.; Tolner, E.A.; Behrens, C.J.; Gross, M.; Soreq, H.; Heinemann, U.; Friedman, A. Acetylcholine- induced seizure-like activity and modified cholinergic gene expression in chronically epileptic rats. Eur. J. Neurosci., 2008, 27(4), 965-975.
123. Maslarova, A.; Salar, S.; Lapilover, E.; Friedman, A.; Veh, R.W.; Heinemann, U. Increased susceptibility to acetylcholine in the entorhinal cortex of pilocarpine-treated rats involves alterations in KCNQ channels. Neurobiol. Dis., 2013, 56C, 14-24.
124. Klaft, Z.J.; Schulz, S.B.; Maslarova, A.; Gabriel, S.; Heinemann, U.; Gerevich, Z. Extracellular ATP differentially affects epileptiform activity via purinergic P2X7 and adenosine A1 receptors in naive and chronic epileptic rats. Epilepsia, 2012, 53(11), 1978-1986.
125. Zahn, R.K.; Tolner, E.A.; Derst, C.; Gruber, C.; Veh, R.W.; Heinemann, U. Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of kainate-treated chronic epileptic rats. Neurobiol. Dis., 2008, 29(2), 186-200.
126. Streit, A.K.; Derst, C.; Wegner, S.; Heinemann, U.; Zahn, R.K.; Decher, N. RNA editing of Kv1.1 channels may account for reduced ictogenic potential of 4-aminopyridine in chronic epileptic rats. Epilepsia, 2011, 52(3), 645-648.
127. Zahn, R.K.; Liotta, A.; Kim, S.; Sandow, N.; Heinemann, U. Reduced ictogenic potential of 4-aminopyridine in the hippocampal region in the pilocarpine model of epilepsy. Neurosci. Lett., 2012, 513(2), 124-128.
128. Quilichini, P.P.; Diabira, D.; Chiron, C.; Milh, M.; Ben-Ari, Y.; Gozlan, H. Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro. Epilepsia, 2003, 44(11), 1365-1374.
129. Gabriel, S.; Kivi, A.; Eilers, A.; Kovács, R.; Heinemann, U. Effects of barium on stimulus-induced rises in [K+]o in juvenile rat hippocampal area CA1. Neuroreport, 1998, 9(11), 2583-2587.
130. Hablitz, J.J.; Heinemann, U. Alterations in the microenvironment during spreading depression associated with epileptiform activity in the immature neocortex. Brain Res. Dev. Brain Res., 1989, 46(2), 243-252.
131. Heinemann, U.; Albrecht, D.; Beck, H.; Ficker, E.; von Haebler, D.; Stabel, J. Delayed K+ regulation and K+ current maturation as factors of enhanced epileptogenicity during ontogenesis of the hippocampus of rats. Epilepsy Res. Suppl., 1992, 9, 107-114.
132. Gutiérrez, R.; Heinemann, U. Synaptic reorganization in explanted cultures of rat hippocampus. Brain Res., 1999, 815(2), 304-316.
133. Franck, J.E.; Pokorny, J.; Kunkel, D.D.; Schwartzkroin, P.A. Physiologic and morphologic characteristics of granule cell circuitry in human epileptic hippocampus. Epilepsia, 1995, 36(6), 543-558.
134. Mello, L.E.; Cavalheiro, E.A.; Tan, A.M.; Kupfer, W.R.; Pretorius, J.K.; Babb, T.L.; Finch, D.M. Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: cell loss and mossy fiber sprouting. Epilepsia, 1993, 34(6), 985-995.
135. Albus, K.; Heinemann, U.; Kovács, R. Network activity in hippocampal slice cultures revealed by long-term in vitro recordings. J. Neurosci. Methods, 2013, 217(1-2), 1-8.
136. Xiang, Z.; Hrabetova, S.; Moskowitz, S.I.; Casaccia-Bonnefil, P.; Young, S.R.; Nimmrich, V.C.; Tiedge, H.; Einheber, S.; Karnup, S.; Bianchi, R.; Bergold, P.J. Long-term maintenance of mature hippocampal slices in vitro. J. Neurosci. Methods, 2000, 98(2); 145-154.
137. Dyhrfjeld-Johnsen, J.; Berdichevsky, Y.; Swiercz, W.; Sabolek, H.; Staley, K.J. Interictal spikes precede ictal discharges in an organotypic hippocampal slice culture model of epileptogenesis. J. Clin. Neurophysiol., 2010, 27(6), 418-424.
138. Berdichevsky, Y.; Dzhala, V.; Mail, M.; Staley, K.J. Interictal spikes, seizures and ictal cell death are not necessary for posttraumatic epileptogenesis in vitro. Neurobiol. Dis., 2012, 45(2), 774-785.
139. Kovács, R.; Gutiérrez, R.; Kivi, A.; Schuchmann, S.; Gabriel, S.; Heinemann, U. Acute cell damage after low Mg2+-induced epileptiform activity in organotypic hippocampal slice cultures. Neuroreport, 1999, 10(2), 207-213.
140. Kovács, R.; Rabanus, A.; Otáhal, J.; Patzak, A.; Kardos, J.; Albus, K.; Heinemann, U.; Kann, O. Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and entorhinal cortex slices. J. Neurosci., 2009, 29(26), 8565-8577.
141. Albus, K.; Wahab, A.; Heinemann, U. Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures. Br. J. Pharmacol., 2008, 154(3), 709-724.
142. Wahab, A.; Heinemann, U.; Albus, K. Effects of gammaaminobutyric acid (GABA) agonists and a GABA uptake inhibitor on pharmacoresistant seizure like events in organotypic hippocampal slice cultures. Epilepsy Res., 2009, 86(2-3), 113-123.
143. Frantseva, M.V.; Velazquez, J.L.; Hwang, P.A.; Carlen, P.L. Free radical production correlates with cell death in an in vitro model of epilepsy. Eur. J. Neurosci., 2000, 12(4), 1431-1439.
144. Routbort, M.J.; Bausch, S.B.; McNamara, J.O. Seizures, cell death, and mossy fiber sprouting in kainic acid-treated organotypic hippocampal cultures. Neuroscience, 1999, 94(3), 755-765.
145. Tinnes, S.; Schäfer, M.K.; Flubacher, A.; Münzner, G.; Frotscher, M.; Haas, C.A. Epileptiform activity interferes with proteolytic processing of Reelin required for dentate granule cell positioning. FASEB J., 2011, 25(3), 1002-1013.
146. Morin-Brureau, M.; Lebrun, A.; Rousset, M.C.; Fagni, L.; Bockaert, J.; de Bock, F.; Lerner-Natoli, M. Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: role of VEGF signaling pathways. J. Neurosci., 2011, 31(29), 10677-10688.
147. Kovács, R.; Papageorgiou, I.; Heinemann, U. Slice cultures as a model to study neurovascular coupling and blood brain barrier in vitro. Cardiovasc. Psychiatry Neurol., 2011, 2011:646958.
148. Theyel, B.B.; Kohrman, M.H.; Frim, D.M.; van Drongelen, W. Network variability across human tissue samples in vitro: the problem and a solution. J. Clin. Neurophysiol., 2010, 27(6), 412-417.
149. Dudek, F.E.; Wuarin, J.P.; Tasker, J.G.; Kim, Y.I.; Peacock, W.J. Neurophysiology of neocortical slices resected from children un dergoing surgical treatment for epilepsy. J. Neurosci. Methods, 1995, 59(1), 49-58.
150. Schwartzkroin, P.A.; Knowles, W.D. Intracellular study of human epileptic cortex: in vitro maintenance of epileptiform activity? Science, 1984, 223(4637), 709-712.
151. Köhling, R.; Qü, M., Zilles, K.; Speckmann, E.J. Current-sourcedensity profiles associated with sharp waves in human epileptic neocortical tissue. Neuroscience, 1999, 94(4), 1039-1050.
152. Wozny, C.; Knopp, A.; Lehmann, T.N.; Heinemann, U.; Behr, J. The subiculum: a potential site of ictogenesis in human temporal lobe epilepsy. Epilepsia, 2005, 46(Suppl 5), 17-21.
153. Wittner, L.; Huberfeld, G.; Clémenceau, S.; Eross, L.; Dezamis, E.; Entz, L.; Ulbert, I.; Baulac, M.; Freund, T.F.; Maglóczky, Z.; Miles, R. The epileptic human hippocampal cornu ammonis 2 region generates spontaneous interictal-like activity in vitro. Brain, 2009, 132(Pt 11), 3032-3046.
154. Gabriel, S.; Njunting, M.; Pomper, J.K.; Merschhemke, M.; Sanabria, E.R.; Eilers, A.; Kivi, A.; Zeller, M.; Meencke, H.J.; Cavalheiro, E.A.; Heinemann, U., Lehmann, T.N. Stimulus and potassium- induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis. J. Neurosci., 2004, 24(46), 10416-10430.
155. Huberfeld, G.; Menendez de la Prida, L.; Pallud, J.; Cohen, I.; Le Van
156. Avoli, M.; Louvel, J.; Drapeau, C.; Pumain, R.; Kurcewicz, I. GABAA-mediated inhibition and in vitro epileptogenesis in the human neocortex. J. Neurophysiol., 1995, 73(2), 468-484.
157. Avoli, M.; Louvel, J.; Pumain, R.; Köhling, R. Cellular and molecular mechanisms of epilepsy in the human brain. Prog. Neurobiol., 2005, 77(3), 166-200.
158. Klitgaard, H.; Matagne, A.; Schachter, S.C.; White, H.S. Animal and Translational Models of the Epilepsies in Animal and Translational Models for CNS Drug Discovery Vol. 2. In: Neurological Disorders; McArthur, R.; Borsini, F., Eds.; Academic Press, 2008, Pages 311-335.
159. Koh, S.; Storey, T.W.; Santos, T.C.; Mian, A.Y.; Cole, A.J. Earlylife seizures in rats increase susceptibility to seizure-induced brain injury in adulthood. Neurology, 1999, 53(5), 915-921.
160. Cavalleri, G.L.; Weale, M.E.; Shianna, K.V.; Singh, R.; Lynch, J.M.; Grinton, B.; Szoeke, C.; Murphy, K.; Kinirons, P.; O'Rourke, D.; Ge, D.; Depondt, C.; Claeys, K.G.; Pandolfo, M.; Gumbs, C.; Walley, N.; McNamara, J.; Mulley, J.C.; Linney, K.N.; Sheffield, L.J.; Radtke, R.A.; Tate, S.K.; Chissoe, S.L.; Gibson, R.A.; Hosford, D.; Stanton, A.; Graves, T.D.; Hanna, M.G.; Eriksson, K.; Kantanen, A.M.; Kalviainen, R.; O'Brien, T.J.; Sander, J.W., Duncan, J.S.; Scheffer, I.E.; Berkovic, S.F.; Wood, N.W.; Doherty, C.P.; Delanty, N.; Sisodiya, S.M.; Goldstein, D.B. Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol., 2007, 6(11), 970-980.
161. Löscher, W.; Klotz, U.; Zimprich. F; Schmidt, D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, 2009, 50(1), 1-23.
162. Kasperaviciute, D.; Catarino, C.B.; Heinzen, E.L.; Depondt, C.; Cavalleri, G.L.; Caboclo, L.O.; Tate, S.K.; Jamnadas-Khoda, J.; Chinthapalli, K.; Clayton, L.M.; Shianna, K.V.; Radtke, R.A.; Mikati, M.A.; Gallentine, W.B.; Husain, A.M.; Alhusaini, S.; Leppert, D.; Middleton, L.T.; Gibson, R.A.; Johnson, M.R.; Matthews, P.M.; Hosford, D.; Heuser, K.; Amos, L.; Ortega, M.; Zumsteg, D.; Wieser, H.G.; Steinhoff, B.J.; Krämer, G.; Hansen, J.; Dorn, T.; Kantanen, A.M.; Gjerstad, L.; Peuralinna, T.; Hernandez, D.G.; Eriksson, K.J.; Kälviäinen, R.K.; Doherty, C.P.; Wood, N.W.; Pandolfo, M.; Duncan, J.S.; Sander, J.W.; Delanty, N.; Goldstein, D.B.; Sisodiya, S.M. Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain, 2010, 133(Pt 7), 2136-2147.
163. Löscher, W. Animal models of intractable epilepsy. Prog. Neurobiol., 1997, 53(2), 239-258.
164. Frey, L.C. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia, 2003, 44(Suppl 10), 11-17.
165. Kobow, K.; Auvin, S.; Jensen, F.; Löscher, W.; Mody, I.; Potschka, H.; Prince, D.; Sierra, A.; Simonato, M.; Pitkänen, A.; Nehlig, A.; Rho, J.M. Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia, 2012, 53(11), 1868-1876.
166. Friedman, A.; Kaufer, D.; Heinemann, U. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res., 2009, 85(2-3), 142-149.
167. Marchi, N.; Granata, T.; Ghosh, C.; Janigro, D. Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia, 2012, 53(11), 1877-1886.
168. Tomkins, O.; Shelef, I.; Kaizerman, I.; Eliushin, A.; Afawi, Z.; Misk, A.; Gidon, M.; Cohen, A.; Zumsteg, D.; Friedman, A. Bloodbrain barrier disruption in post-traumatic epilepsy. J. Neurol. Neurosurg. Psychiatry, 2008, 79(7), 774-777.
169. Ivens, S.; Kaufer, D.; Flores, L.P.; Bechmann, I.; Zumsteg, D.; Tomkins, O.; Seiffert, E.; Heinemann, U.; Friedman, A. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain, 2007, 130(Pt 2), 535-547.
170. David, Y.; Cacheaux, L.P.; Ivens, S.; Lapilover, E.; Heinemann, U.; Kaufer, D.; Friedman, A. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis? J. Neurosci., 2009, 29(34), 10588-10599.
171. Aronica, E.; Crino, P.B. Inflammation in epilepsy: clinical observations. Epilepsia, 2011, 52(Suppl 3), 26-32.
172. Aronica, E.; Ravizza, T.; Zurolo, E.; Vezzani, A. Astrocyte immune responses in epilepsy. Glia, 2012, 60(8), 1258-1268.
173. Vezzani, A.; Aronica, E.; Mazarati, A.; Pittman, Q.J. Epilepsy and brain inflammation. Exp. Neurol., 2013, 244, 11-21.
174. Haberlandt, E.; Rauchenzauner, M.; Morass, M.; Wondrak, P.; Bürgi, S.S.; Rostásy, K.; Karall, D. Matrix-metalloproteinases and proinflammatory cytokines in children with febrile convulsions and epilepsy-Cause or consequence? Epilepsy Res., 2013, 105(1-2), 225-228.
175. Holtman, L.; van Vliet, E.A.; Aronica, E.; Wouters, D.; Wadman, W.J.; Gorter, J.A. Blood plasma inflammation markers during epileptogenesis in post-status epilepticus rat model for temporal lobe epilepsy. Epilepsia, 2013, 54(4), 589-595.
176. Heinemann, U.; Kaufer, D.; Friedman, A. Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia, 2012, 60(8), 1251-1257.
177. Pillai, D.R., Shanbhag, N.C.; Dittmar, M.S.; Bogdahn, U.; Schlachetzki, F. Neurovascular protection by targeting early bloodbrain barrier disruption with neurotrophic factors after ischemiareperfusion in rats. J. Cereb. Blood Flow Metab., 2013, 33(4), 557-566.
178. Sanagi, T.; Yabe, T.; Yamada, H. Adenoviral gene delivery of pigment epithelium-derived factor protects striatal neurons from quinolinic acid-induced excitotoxicity. J. Neuropathol. Exp. Neurol., 2010, 69(3), 224-233.
179. Craword, S.E.; Fitchev, P.; Veliceasa, D.; Volpert, O.V. The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder? Expert Opin. Drug Discov., 2013, 8(7), 769-792.
180. Jiang, J.; Ganesh, T.; Du, Y.; Quan, Y.; Serrano, G.; Qui, M.; Speigel, I.; Rojas, A.; Lelutiu, N.; Dingledine, R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(8), 3149-3154.
181. Sotgiu, S.; Murrighile, M.R.; Constantin, G. Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report. BMC Neurol., 2010, 10:84.
182. Marchi, N.; Granata, T.; Freri, E.; Ciusani, E.; Ragona, F.; Puvenna, V.; Teng, Q.; Alexopolous, A.; Janigro, D. Efficacy of antiinflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One, 2011, 6(3), e18200.
183. Dedeurwaerdere, S.; Friedman, A.; Fabene, P.F.; Mazarati, A.; Murashima, Y.L.; Vezzani, A.; Baram, T.Z. Finding a better drug for epilepsy: antiinflammatory targets. Epilepsia, 2012, 53(7), 1113-1118.
184. Bankstahl, J.P.; Kuntner, C.; Abrahim, A.; Karch, R.; Stanek, J.; Wanek, T.; Wadsak, W.; Kletter, K.; Müller, M.; Löscher, W.; Langer, O. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J. Nucl. Med., 2008, 49(8), 1328-1335.
185. Bennewitz, M.F.; Saltzman, W.M. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics, 2009, 6(2), 323-336.
186. Vezzani, A. Before epilepsy unfolds: finding the epileptogenesis switch. Nat. Med., 2012, 18(11), 1626-1627.
187. Zeng, L.H.; Rensing, N.R.; Wong, M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci., 2009, 29(21), 6964-6972.
188. Buckmaster, P.S.; Ingram, E.A.; Wen, X. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci., 2009, 29(25), 8259-8269.
189. Van Vliet, E.A.; Forte, G.; Holtman, L.; den Burger, J.C.; Sinjewel, A.; de Vries, H.E.; Aronica, E.; Gorter, J.A. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia, 2012, 53(7), 1254-1263.
190. Sliwa, A.; Plucinska, G.; Bednarczyk, J.; Lukasiuk, K. Posttreatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci. Lett., 2012, 509(2), 105-109.
191. D'Antuono, M.; Louvel, J.; Köhling, R.; Mattia, D.; Bernasconi, A.; Olivier, A.; Turak, B.; Devaux, A.; Pumain, R.; Avoli, M. GABAA receptor-dependent synchronization leads to ictogenesis in the human dysplastic cortex. Brain, 2004, 127(Pt 7), 1626-1640.
192. Bausch, S.B.; Chavkin, C. Changes in hippocampal circuitry after pilocarpine-induced seizures as revealed by opioid receptor distribution and activation. J. Neurosci., 1997, 17(1), 477-492.
193. Karlócai, M.R.; Tóth, K.; Watanabe, M.; Ledent, C.; Juhász, G.; Freund, T.F.; Maglóczky, Zs. Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy. PLoS One, 2011, 6(11), e27196.
194. Rouach, N.; Koulakoff, A.; Abudara, V.; Willecke, K.; Giaume, C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science, 2008, 322(5907), 1551-1555.
195. Gutiérrez, R.; Heinemann, U. Co-existence of GABA and Glu in the hippocampal granule cells: implications for epilepsy. Curr. Top. Med. Chem., 2006, 6(10), 975-978.